Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 years. Unsupervised clustering identified groups of patients based on FlowSOM‐derived cell population percentages. In addition, we investigated immunophenotypic patterns in World Health Organization (WHO) patient classes and NPM1 mut subclasses, both at the cell population and the individual marker level. Some WHO classes, for example, AML with t(8;21)(q22;q22)/ RUNX1::RUNX1T1 or t(15;17)(q24;q21)/ PML::RARA , showed homogeneous immunophenotypes. Characterization of maturation arrest using FlowSOM confirmed maturation arrest at early stages in distinct WHO classes. Finally, a machine learning model was trained to predict WHO genetic classes from immunophenotypic data. The model allowed accurate prediction in 77% of cases, reproducible in an independent validation cohort. In conclusion, we show that EuroFlow standardized protocols allow analysis of multi‐centric data measured over an extended period of time. Computational analysis demonstrated inter‐ and intrapatient immunophenotypic heterogeneity and allowed prediction of genetic abnormalities.
No takes yet. Share an insight, caveat, or question.
Bonte et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: